About one year ago, the Association for Molecular Pathology (AMP), with liaison representation from the American College of Medical Genetics and Genomics (ACMG), American Society of Clinical Oncology (ASCO), and College of American Pathologists (CAP), released a guideline on reporting somatic cancer variants. 

The AMP guidelines were created to address a specific need: oncologists required a standardized presentation of somatic variants in a diagnostic test report in order to help them quickly understand the results and the importance of each variant in the context of the patient’s disease. Several groups have published “levels of evidence” for the categorization of somatic variants, however the molecular pathology field lacked a single standard. The authors of the AMP guidelines collected and studied reporting schemata from the field and laid out a tier-based reporting system, with defined levels of evidence for each variant’s ability to predict response or resistance to a therapy in the context of a disease, or association with prognostic or diagnostic significance in a disease.  The guidelines were researched and developed by the leading industry organizations without commercial association and are positioned to become an industry standard. 

This webinar focuses on the methodology and benefits of mapping the AMP guideline's Levels of Evidence (LOEs) to somatic variants, addresses the complexity that comes with this process, and explores what industry leaders are doing to address that complexity.